TrkA inhibitor compound 23 is primarily used in research settings to study the role of TrkA receptors in various biological processes. It is particularly valuable in investigating the signaling pathways associated with nerve growth factor (NGF) and its impact on cell survival, differentiation, and proliferation. This compound is often utilized in preclinical studies to explore its potential therapeutic effects in conditions where TrkA signaling is dysregulated, such as certain types of cancer, chronic pain, and neurodegenerative diseases. By inhibiting TrkA activity, researchers can better understand the mechanisms underlying these conditions and assess the compound's efficacy as a targeted treatment. Additionally, it serves as a tool for developing and testing new therapeutic strategies aimed at modulating TrkA signaling pathways.